Literature DB >> 18447776

Evaluation of twice-daily, low-dose trilostane treatment administered orally in dogs with naturally occurring hyperadrenocorticism.

Matthew A Vaughan1, Edward C Feldman, Bruce R Hoar, Richard W Nelson.   

Abstract

OBJECTIVE: To evaluate the effects of twice-daily oral administration of a low-dose of trilostane treatment and assess the duration of effects after once-daily trilostane administration in dogs with naturally occurring hyperadrenocorticism (NOH).
DESIGN: Prospective study. ANIMALS: 28 dogs with NOH. PROCEDURES: 22 dogs received 0.5 to 2.5 mg of trilostane/kg (0.23 to 1.14 mg/lb) orally every 12 hours initially. At intervals, dogs were reevaluated; owner assessment of treatment response was recorded. To assess drug effect duration, 16 of the 22 dogs and 6 additional dogs underwent 2 ACTH stimulation tests 3 to 4 hours and 8 to 9 hours after once-daily trilostane administration.
RESULTS: After 1 to 2 weeks, mean trilostane dosage was 1.4 mg/kg (0.64 mg/lb) every 12 hours (n = 22 dogs; good response [resolution of signs], 8; poor response, 14). Four to 8 weeks later, mean dosage was 1.8 mg/kg (0.82 mg/lb) every 12 or 8 hours (n = 21 and 1 dogs, respectively; good response, 15; poor response, 5; 2 dogs were ill). Eight to 16 weeks after the second reevaluation, remaining dogs had good responses (mean dosages, 1.9 mg/kg [0.86 mg/lb], q 12 h [n = 13 dogs] and 1.3 mg/kg [0.59 mg/lb], q 8 h [3]). At 3 to 4 hours and 8 to 9 hours after once-daily dosing, mean post-ACTH stimulation serum cortisol concentrations were 2.60 and 8.09 Pg/dL, respectively. CONCLUSIONS AND CLINICAL RELEVANCE: In dogs with NOH, administration of trilostane at low doses every 12 hours was effective, although 2 dogs became ill during treatment. Drug effects diminished within 8 to 9 hours. Because of potential adverse effects, lower doses should be evaluated.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18447776     DOI: 10.2460/javma.232.9.1321

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  10 in total

1.  The influence of trilostane on steroid hormone metabolism in canine adrenal glands and corpora lutea-an in vitro study.

Authors:  C Ouschan; M Lepschy; F Zeugswetter; E Möstl
Journal:  Vet Res Commun       Date:  2011-11-25       Impact factor: 2.459

Review 2.  Update on the use of trilostane in dogs.

Authors:  Julie Lemetayer; Shauna Blois
Journal:  Can Vet J       Date:  2018-04       Impact factor: 1.008

3.  Long-term outcome of myotonia associated with hyperadrenocorticism in 2 dogs.

Authors:  Noriyuki Nagata; Masashi Yuki
Journal:  Can Vet J       Date:  2015-09       Impact factor: 1.008

4.  Comparison of adrenocorticotropic hormone stimulation test results started 2 versus 4 hours after trilostane administration in dogs with naturally occurring hyperadrenocorticism.

Authors:  C M Bonadio; E C Feldman; T A Cohen; P H Kass
Journal:  J Vet Intern Med       Date:  2014-05-26       Impact factor: 3.333

5.  Effect of trilostane and mitotane on aldosterone secretory reserve in dogs with pituitary-dependent hyperadrenocorticism.

Authors:  L E Reid; E N Behrend; L G Martin; R J Kemppainen; C R Ward; J C Lurye; T C Donovan; H P Lee
Journal:  J Vet Intern Med       Date:  2014-01-08       Impact factor: 3.333

6.  Cortisol Concentrations in Well-Regulated Dogs with Hyperadrenocorticism Treated with Trilostane.

Authors:  J N Midence; K J Drobatz; R S Hess
Journal:  J Vet Intern Med       Date:  2015-09-16       Impact factor: 3.333

7.  Pre-trilostane and three-hour post-trilostane cortisol to monitor trilostane therapy in dogs.

Authors:  L Macfarlane; T Parkin; I Ramsey
Journal:  Vet Rec       Date:  2016-11-01       Impact factor: 2.695

8.  Clinical Relationship between Cholestatic Disease and Pituitary-Dependent Hyperadrenocorticism in Dogs: A Retrospective Case Series.

Authors:  K-H Kim; S-M Han; K-O Jeon; H-T Kim; Q Li; M-O Ryu; W-J Song; S-C Park; H-Y Youn
Journal:  J Vet Intern Med       Date:  2017-01-08       Impact factor: 3.333

9.  Effect of trilostane on hormone and serum electrolyte concentrations in dogs with pituitary-dependent hyperadrenocorticism.

Authors:  C Griebsch; C Lehnert; G J Williams; K Failing; R Neiger
Journal:  J Vet Intern Med       Date:  2013-12-16       Impact factor: 3.333

10.  Laboratory assessment of trilostane treatment in dogs with pituitary-dependent hyperadrenocorticism.

Authors:  Carolina Arenas Bermejo; Dolores Pérez Alenza; Paula García San José; Lidia Llauet; Laura Pérez-López; Carlos Melián; Edward C Feldman
Journal:  J Vet Intern Med       Date:  2020-06-13       Impact factor: 3.333

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.